Pregnancy-associated plasma protein-A (
PAPP-A) and its homolog PAPP-A2 are
enzymes that modulate the availability and mitogenic activity of
insulin-like growth factor-I (
IGF-I).
PAPP-A has been implicated in numerous
cancers but reports on PAPP-A2 in
malignancy are non-existent. In a prospective observational study of 689 patients under suspicion of
lung cancer, we examined levels of
PAPP-A and PAPP-A2 and their relationship with mortality. Serum
PAPP-A and PAPP-A2 concentrations were determined in pre-diagnostic blood samples using ELISA, and immunohistochemical staining of
PAPP-A and PAPP-A2 was performed in malignant tissue from five operable patients. A total of 144 patients were diagnosed with
lung cancer, whereas the diagnosis was rejected in 545 subjects, who served as a control group. PAPP-A2 concentrations were higher in patients with
lung cancer [median (IQR): 0.33 (0.21-0.56) ng/mL] than in controls [0.27 (0.17-0.39) ng/mL], p < 0.001, whereas
PAPP-A levels did not differ. Presence of
PAPP-A and PAPP-A2 were confirmed in
tumor specimens, and staining occurred in a heterogeneous pattern. Patients were observed for a median (range) of 7 (6; 8) years, during which 114 patients (79.2%) died. Patient mortality differed according to PAPP-A2 tertile (p < 0.001). PAPP-A2 was associated with mortality with an unadjusted hazard ratio (95% CI) per doubling in
protein concentration of 1.30 (1.12; 1.53), p = 0.001. In a multivariable model adjusted for age, sex, and BMI, PAPP-A2 remained predictive of the endpoint with a hazard ratio per doubling in
protein concentration of 1.25 (1.05; 1.48), p = 0.013. Collectively, PAPP-A2, but not
PAPP-A, is elevated in patients with
lung cancer and associated with mortality. This novel role of PAPP-A2 in
cancer warrants further functional studies as well as validation in external cohorts.